ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$2.34 USD
-0.17 (-6.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.31 -0.03 (-1.28%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for ProPhase Labs, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 17 | 18 | 8 | 1 |
Receivables | 36 | 37 | 38 | 3 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 4 | 5 | 3 | 1 |
Other Current Assets | 2 | 2 | 2 | 1 | 0 |
Total Current Assets | 48 | 61 | 61 | 16 | 10 |
Net Property & Equipment | 13 | 7 | 6 | 4 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 3 | 0 |
Deferred Charges | 7 | 0 | 0 | 0 | 0 |
Intangibles | 18 | 14 | 17 | 2 | 0 |
Deposits & Other Assets | 2 | 1 | 1 | 2 | 0 |
Total Assets | 92 | 88 | 89 | 31 | 12 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 6 | 7 | 4 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 2 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 1 | 2 | 0 | 0 |
Income Taxes Payable | 3 | 4 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 5 | 6 | 2 | 0 |
Total Current Liabilities | 21 | 16 | 16 | 6 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 0 | 0 |
Convertible Debt | 7 | 2 | 10 | 10 | 0 |
Long-Term Debt | 3 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 4 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 43 | 24 | 31 | 21 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 119 | 109 | 105 | 62 | 60 |
Retained Earnings | -5 | 12 | 3 | -4 | -2 |
Other Equity | 0 | 1 | 0 | 0 | 0 |
Treasury Stock | 64 | 58 | 48 | 47 | 47 |
Total Shareholder's Equity | 49 | 64 | 59 | 11 | 11 |
Total Liabilities & Shareholder's Equity | 92 | 88 | 89 | 31 | 12 |
Total Common Equity | 49 | 64 | 59 | 11 | 11 |
Shares Outstanding | 18.00 | 16.20 | 15.40 | 15.10 | 11.50 |
Book Value Per Share | 2.74 | 3.93 | 3.81 | 0.70 | 0.98 |
Fiscal Year End for ProPhase Labs, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 2 | 5 | 3 | 9 |
Receivables | 33 | 35 | 36 | 39 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 4 | 4 | 5 | 4 |
Other Current Assets | 5 | 4 | 2 | 3 | 4 |
Total Current Assets | 44 | 45 | 48 | 50 | 55 |
Net Property & Equipment | 15 | 13 | 13 | 13 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 12 | 10 | 7 | 4 | 1 |
Intangibles | 16 | 17 | 18 | 18 | 19 |
Deposits & Other Assets | 1 | 1 | 2 | 2 | 2 |
Total Assets | 94 | 90 | 92 | 92 | 91 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 12 | 9 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | 4 | 2 | 2 | 2 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 3 | 3 | 3 | 3 | 2 |
Other Current Liabilities | 7 | 4 | 5 | 4 | 5 |
Total Current Liabilities | 28 | 24 | 21 | 16 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 3 | 1 | 1 | 1 |
Convertible Debt | 7 | 7 | 7 | 7 | 10 |
Long-Term Debt | 3 | 3 | 3 | 0 | 0 |
Non-Current Capital Leases | 4 | 4 | 4 | 4 | 1 |
Other Non-Current Liabilities | 2 | 2 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 50 | 45 | 43 | 35 | 32 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 126 | 120 | 119 | 118 | 114 |
Retained Earnings | -17 | -11 | -5 | 4 | 9 |
Other Equity | 0 | 0 | 0 | -1 | 1 |
Treasury Stock | 64 | 64 | 64 | 64 | 64 |
Total Shareholder's Equity | 44 | 45 | 49 | 56 | 59 |
Total Liabilities & Shareholder's Equity | 94 | 90 | 92 | 92 | 91 |
Total Common Equity | 44 | 45 | 49 | 56 | 59 |
Shares Outstanding | 19.00 | 18.00 | 18.00 | 16.80 | 17.10 |
Book Value Per Share | 2.32 | 2.49 | 2.74 | 3.36 | 3.47 |